ClinicalTrials.gg
CompletedNCT01626872Updated Jan 5, 2026Results posted

Long-Term Study of MP-214 in Patients With Schizophrenia

A Phase 2/3 interventional study of MP-214 3mg and MP-214 6mg in Schizophrenia, sponsored by Tanabe Pharma Corporation. Completed at 3 sites in 3 countries. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Tanabe Pharma Corporation · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
11th of 23
254 · median 129
Started
2012
with 4 others
Phase 2/3
6 of 23
1 open now
Registered
10th of 23
by date
Lead sponsor
6 of 23
Tanabe Pharma Corporation

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 11th largest by enrollment, is one of 5 that started in 2012, is one of 6 in phase 2/3, and was the 10th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Antipsychotic Agents
  • Mental Disorder
  • Psychotropic Drugs
  • Dopamine Agents
  • Risperidone
  • Central Nervous System Agents
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from the patient before the completion of Study A002-A4
  • Patients who have completed the A002-A4 study

Exclusion criteria

Exclusion Criteria:

  • Patients who are experiencing ongoing, uncontrolled, adverse events (AEs), as judged by the investigator (or subinvestigator)

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    MP-214 3mg

    Drug: MP-214 3mg

  • Experimental
    MP-214 6mg

    Drug: MP-214 6mg

  • Experimental
    MP-214 9mg

    Drug: MP-214 9mg

  • Active comparator
    Risperidone 4mg

    Drug: Risperidone 4mg

Interventions

  • In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

  • In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

  • In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

  • In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    The Numbers show Subjects with at least one Adverse Event

    Time frame: Up to 60 weeks (Treatment Period (48 weeks) and Follow-up Period (12 weeks))

07

Results

Posted Apr 12, 2021

Participant flow

Participant flow — Overall Study
MilestoneMP-214 3mgMP-214 6mgMP-214 9mg
Started8110958
Completed294334
Not completed526624
Withdrew: Physician decision1396
Withdrew: Withdrawal by subject19278
Withdrew: Adverse event (including death)20288
Withdrew: Protocol violation (including pregnancy)022

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability

The Numbers show Subjects with at least one Adverse Event

Time frame:
Up to 60 weeks (Treatment Period (48 weeks) and Follow-up Period (12 weeks))
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsMP-214 3mgMP-214 6mgMP-214 9mg
Number of Participants With Adverse Events as a Measure of Safety and Tolerability679250

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MP-214 3mg—14/81 (17.3%)55/81 (67.9%)
MP-214 6mg—33/109 (30.3%)72/109 (66.1%)
MP-214 9mg—14/58 (24.1%)42/58 (72.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventMP-214 3mgMP-214 6mgMP-214 9mg
SchizophreniaPsychiatric disorders9/8126/10911/58
InsomniaPsychiatric disorders0/811/1092/58
Suicide attemptPsychiatric disorders0/812/1090/58
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/810/1091/58
Completed suicidePsychiatric disorders0/810/1091/58
Schizophrenia, paranoid typePsychiatric disorders1/811/1091/58
Ankle fractureInjury, poisoning and procedural complications1/810/1090/58
Ligament sprainInjury, poisoning and procedural complications1/810/1090/58
ScarInjury, poisoning and procedural complications1/810/1090/58
Skin scar contractureInjury, poisoning and procedural complications1/810/1090/58
Most frequent other events
Showing 10 of 27
Most frequent other events
EventMP-214 3mgMP-214 6mgMP-214 9mg
NasopharyngitisInfections and infestations21/8113/10913/58
SchizophreniaPsychiatric disorders12/8112/10911/58
AkathisiaNervous system disorders15/8115/1092/58
InsomniaPsychiatric disorders4/8112/1098/58
ConstipationGastrointestinal disorders9/815/1096/58
HeadacheNervous system disorders9/817/1094/58
Tinea pedisInfections and infestations0/813/1096/58
EczemaSkin and subcutaneous tissue disorders1/815/1096/58
Weight increasedInvestigations4/8111/1092/58
Extrapyramidal disorderNervous system disorders8/817/1094/58

Baseline characteristics

Age, Continuous
Age, Continuous(years)MP-214 3mgMP-214 6mgMP-214 9mgTotal
Mean38.0 ± 11.140.8 ± 11.342.5 ± 8.940.3 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)MP-214 3mgMP-214 6mgMP-214 9mgTotal
Female405620116
Male415338132
08

Study locations

3 sites
  • Sapporo, Hokkaido, Japan
  • Seoul, South Korea
  • Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2021, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2012
First posted
Jun 25, 2012
Start
Sep 2012
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results first posted
Apr 12, 2021
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01626872
Responsible party
Sponsor
First posted
Jun 25, 2012
Start date
Sep 2012
Primary completion
Oct 2016
Completion
Oct 2016
Results posted
Apr 12, 2021
Last update
Jan 5, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion